← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
101	101 Design Therapeutics DSGN $656M	–	–	–	–
102	102 Precision BioSciences DTIL $170M	–	–	–	–
103	103 Editas Medicine EDIT $375M	–	–	–	–
104	104 enGene Therapeutics ENGN $115M	–	–	–	–
105	105 Estrella Immunopharma ESLA $23.3M	–	–	–	–
106	106 FibroBiologics FBLG $7.08M	–	–	–	–
107	107 4D Molecular Therapeutics FDMT $711M	–	–	–	–
108	108 Fulgent Genetics FLGT $587M	–	–	–	–
109	FRLN 109 DELISTED Freeline Therapeutics Holdings plc American Depositary Shares FRLN	–	–	–	–
110	110 DELISTED Generation Bio GBIO	–	–	–	–
111	111 CytoMed Therapeutics GDTC $10.4M	–	–	–	–
112	112 Guardant Health GH $22.3B	–	–	–	–
113	GMDA 113 DELISTED Gamida Cell Ltd. Ordinary Shares GMDA	–	–	–	–
114	114 Corgi Genomics & Precision Medicine ETF GNMX $1.68M	–	–	–	–
115	115 Global X Genomics & Biotechnology ETF GNOM $99.5M	–	–	–	–
116	116 Genprex GNPX $1.88M	–	–	–	–
117	117 Genenta Science GNTA $32.3M	–	–	–	–
118	118 GRAIL Inc GRAL $6.05B	–	–	–	–
119	GRCL 119 DELISTED Gracell Biotechnologies Inc. American Depositary Shares GRCL	–	–	–	–
120	GRML 120 Greenland Mines Ltd GRML $92.9M	–	–	–	–
121	GTH 121 DELISTED Genetron Holdings Limited ADS GTH	–	–	–	–
122	122 Fractyl Health GUTS $55.2M	–	–	–	–
123	123 Franklin Genomic Advancements ETF HELX $29.8M	–	–	–	–
124	124 iShares Genomics Immunology and Healthcare ETF IDNA $317M	–	–	–	–
125	125 Immix Biopharma IMMX $720M	–	–	–	–